The Oncologic Drugs Advisory Committee may have voted narrowly for accelerated approval of Talon Therapeutics Inc. ’s Marqibo (vincristine sulfate liposomes injection), but even the yeas expressed nervousness about the design and even the feasibility of the confirmatory Phase III trial of the drug for advanced acute lymphoblastic leukemia, which is already under way.
ODAC Vote
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?